Clinical Trials Logo
  1. Home
  2. Dry Eye Syndromes
  3. NCT06337981
  4. Details
NCT06337981 Clinical Trial

Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

Dry Eye Syndromes Clinical Trial

Official title:
A Phase 2 Multicenter, Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AJU-S56 in Patients With Dry Eye Disease

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06337981
Other study ID # 21DE20901
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 22, 2021
Est. completion date November 28, 2022

Study information
Verified date April 2024
Source AJU Pharm Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease.

Recruitment information / eligibility
Status Completed
Enrollment 99
Est. completion date November 28, 2022
Est. primary completion date June 14, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Male and Female who over 19 years old - Moderate to Severe Dry Eye Disease Patients - Must meet all criteria listed below at least in one eye or both eyes. TCSS (National eye institute (NEI) scale)= 4 Schirmer test(without anesthesia) = 10mm in 5 mins Tear break-up time = 6 secs - Written informed consent to participate in the trial Exclusion Criteria: - Those who have clinically significant eye disease not related to dry eye syndrome - Those who have medical history with intraocular surgery 12months before screening visit - Use of corticosteroid, beta blocker and anticholinergic agent within 4 weeks - Participation in other studies within 4weeks of screening visit

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• (AJU-S56 5% and placebo)
(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
• AJU-S56 5%
(AJU-S56 5%), 1drop/1times, 6times in a day
• Placebo(Vehicle)
Placebo(Vehicle), 1drop/1times, 6times in a day

Locations
Country Name City State
Korea, Republic of AJU Pharm Co., Ltd. Seoul

Sponsors (2)
Lead Sponsor Collaborator
AJU Pharm Co., Ltd. GL Pharm Tech Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Total corneal staining score (TCSS) Total corneal staining score (TCSS) =4 at baseline (Total Max score : 15, bigger socre means worse outcome) WEEK 4(Visit 4) (*Baseline, Visit 2 is performed in Day 0, Week 0)
Secondary LGCSS Lissamine Green Conjunctival Staining Score(Total score : 0~18) WEEK 2(Visit 3), 4(Visit 4), 8(Visit 5), 12(Visit 12) (*Baseline, Visit 2 is performed in Day 0, Week 0)
Secondary TFBUT Tear Film Break Up Time WEEK 2(Visit 3), 4(Visit 4), 8(Visit 5), 12(Visit 12) (*Baseline, Visit 2 is performed in Day 0, Week 0)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A